PURPOSE: To determine if phosphorylated neurofilament heavy chain (pNF-H) released into the bloodstream and the pattern ERG are noninvasive indicators of neurodegeneration in experimental optic neuritis. METHODS: Serum from Myelin oligodendrocyte glycoprotein (MOG)-specific T cell receptor-positive (TCR+) transgenic mice that develop isolated optic neuritis usually without any other characteristic lesions of inflammation or demyelination in the spinal cord and littermates negative for the transgene were assayed for the presence of serum phosphorylated neurofilament H (pNF-H). In vivo measurements of optic nerve and retinal ganglion cell injury were assessed by magnetic resonance imaging (MRI), optical coherence tomography (OCT), and pattern electroretinogram (PERG). Automated two dimensional fluorescence differential in-gel electrophoresis (2D-DIGE) of pooled optic nerve samples, light, and transmission electron micrographs were used to evaluate optic atrophy postmortem. RESULTS: We found an almost 3-fold elevation in serum pNF-H levels in MOG+ mice relative to MOG-littermates (P = 0.02). 2D-DIGE revealed a 3-fold reduction in optic nerve neurofilaments. Visual function assessed by the PERG was reduced by one-quarter (P = 0.033) and latencies increased by 38% (P = 0.036). MOG+ mice with the lowest PERG amplitudes had optic nerve atrophy visualized by MRI. Optic nerve diameters were reduced by one-third (P = 0.0001) and axon counts reduced by more than two-thirds. Histopathology of the spinal cords was normal. CONCLUSIONS: Elevated serum pNF-H levels and the PERG are useful markers of neurodegeneration of the optic nerve in isolated experimental optic neuritis. Our findings suggest that elevations of this axonal protein in patients with optic neuritis who had a poor visual outcome are likely also due to demise of optic nerve axons.
PURPOSE: To determine if phosphorylated neurofilament heavy chain (pNF-H) released into the bloodstream and the pattern ERG are noninvasive indicators of neurodegeneration in experimental optic neuritis. METHODS: Serum from Myelin oligodendrocyte glycoprotein (MOG)-specific T cell receptor-positive (TCR+) transgenic mice that develop isolated optic neuritis usually without any other characteristic lesions of inflammation or demyelination in the spinal cord and littermates negative for the transgene were assayed for the presence of serum phosphorylated neurofilament H (pNF-H). In vivo measurements of optic nerve and retinal ganglion cell injury were assessed by magnetic resonance imaging (MRI), optical coherence tomography (OCT), and pattern electroretinogram (PERG). Automated two dimensional fluorescence differential in-gel electrophoresis (2D-DIGE) of pooled optic nerve samples, light, and transmission electron micrographs were used to evaluate optic atrophy postmortem. RESULTS: We found an almost 3-fold elevation in serum pNF-H levels in MOG+ mice relative to MOG-littermates (P = 0.02). 2D-DIGE revealed a 3-fold reduction in optic nerve neurofilaments. Visual function assessed by the PERG was reduced by one-quarter (P = 0.033) and latencies increased by 38% (P = 0.036). MOG+ mice with the lowest PERG amplitudes had optic nerve atrophy visualized by MRI. Optic nerve diameters were reduced by one-third (P = 0.0001) and axon counts reduced by more than two-thirds. Histopathology of the spinal cords was normal. CONCLUSIONS: Elevated serum pNF-H levels and the PERG are useful markers of neurodegeneration of the optic nerve in isolated experimental optic neuritis. Our findings suggest that elevations of this axonal protein in patients with optic neuritis who had a poor visual outcome are likely also due to demise of optic nerve axons.
Authors: Kurt-Wolfram Sühs; Katharina Hein; Muriel B Sättler; Anke Görlitz; Christoph Ciupka; Kerstin Scholz; Barbara Käsmann-Kellner; Panagiotis Papanagiotou; Nina Schäffler; Cordula Restemeyer; Diana Bittersohl; Andrea Hassenstein; Berthold Seitz; Wolfgang Reith; Klaus Fassbender; Reinhard Hilgers; Christoph Heesen; Mathias Bähr; Ricarda Diem Journal: Ann Neurol Date: 2012-08 Impact factor: 10.422
Authors: Gurumoorthy Krishnamoorthy; Amit Saxena; Lennart T Mars; Helena S Domingues; Reinhard Mentele; Avraham Ben-Nun; Hans Lassmann; Klaus Dornmair; Florian C Kurschus; Roland S Liblau; Hartmut Wekerle Journal: Nat Med Date: 2009-06 Impact factor: 53.440
Authors: V Lehmensiek; S D Süssmuth; J Brettschneider; G Tauscher; S Felk; F Gillardon; H Tumani Journal: J Neuroimmunol Date: 2007-03-26 Impact factor: 3.478
Authors: S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Venu Talla; Rajeshwari Koilkonda; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy Journal: Invest Ophthalmol Vis Sci Date: 2015-01-22 Impact factor: 4.799
Authors: Venu Talla; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy Journal: Invest Ophthalmol Vis Sci Date: 2014-07-11 Impact factor: 4.799
Authors: Axel Petzold; Mike P Wattjes; Fiona Costello; Jose Flores-Rivera; Clare L Fraser; Kazuo Fujihara; Jacqueline Leavitt; Romain Marignier; Friedemann Paul; Sven Schippling; Christian Sindic; Pablo Villoslada; Brian Weinshenker; Gordon T Plant Journal: Nat Rev Neurol Date: 2014-07-08 Impact factor: 42.937
Authors: Sheryl L Herrera; Vanessa L Palmer; Heather Whittaker; Blair Cardigan Smith; Annie Kim; Angela E Schellenberg; Jonathan D Thiessen; Richard Buist; Marc R Del Bigio; Melanie Martin Journal: Magn Reson Insights Date: 2014-11-09
Authors: Gabrielle Frame; Adam Schuller; Matthew A Smith; Samuel D Crish; Christine M Dengler-Crish Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160